| 產(chǎn)品名稱 | PF 03814735 |
| 產(chǎn)品貨號 | Axon 2023 CAS [942487-16-3] MF C23H25F3N6O2MW 474.48 Purity: 98% Optical purity: Optically pure Soluble in DMSO Description Potent, orally bioavailable, ATP-competitive and reversible inhibitor of aurora kinase A (IC50: 0.8 nM) and aurora kinase B (IC50: 5 nM) with potential antineoplastic activity; PF 03814735 also inhibits Flt1, FAK and TrkA with IC50 values of 10, 22, 30 nM respectively; clinical candidate. KEYWORDS:?PF 03814735 | supplier | Aurora inhibitor | PF03814735 | PF-03814735 | CAS [942487-16-3] | Histone | Survivin | Topo | TPX2 | Aurora kinase | antineoplastic activity | Flt1 | FAK | TrkA | clinical candidate |
| 產(chǎn)品價格 | 現(xiàn)貨詢價，電話：010-67529703 |
| 產(chǎn)品規(guī)格 | |
| 產(chǎn)品品牌 | axonmedchem |
| 產(chǎn)品概述 | |
| 產(chǎn)品詳情 |
PF 03814735Axon 2023 CAS [942487-16-3] MF C23H25F3N6O2
DescriptionPotent, orally bioavailable, ATP-competitive and reversible inhibitor of aurora kinase A (IC50: 0.8 nM) and aurora kinase B (IC50: 5 nM) with potential antineoplastic activity; PF 03814735 also inhibits Flt1, FAK and TrkA with IC50 values of 10, 22, 30 nM respectively; clinical candidate. KEYWORDS:?PF 03814735 | supplier | Aurora inhibitor | PF03814735 | PF-03814735 | CAS [942487-16-3] | Histone | Survivin | Topo | TPX2 | Aurora kinase | antineoplastic activity | Flt1 | FAK | TrkA | clinical candidate
ATP-competitive inhibitor of aurora kinase A and B
Chemical nameN-[2-[(1S,4R)-6-[[4-(cyclobutylamino)-5-(trifluoromethyl)-2-pyrimidinyl]amino]-1,2,3,4-tetrahydronaphthalen-1,4-imin-9-yl]-2-oxoethyl]-acetamide Source informationPfizer compound; Sold for research purposes under agreement from Pfizer Inc.Parent CAS No.[942487-16-3] |
| 產(chǎn)品資料 |
